Invokana Lawsuit Filed within days of Latest FDA Warning

Philadelphia, PA: On December 4, the US Food and Drug Administration (FDA) posted to its website a warning with regard to diabetes drugs in the SGLT2 inhibitor class. The concern is the emergence of diabetic ketoacidosis in individuals with type 2 diabetes. Invokana is one of the drugs tagged by the FDA to include warnings about the potential for the life-threatening condition, amongst other Invokana adverse reactions